文献速递心律失常

房颤患者NOAC不适当剂量的结局与驱动因素:系统综述与荟萃分析

Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis.
PubMed 文献 · Heart · 2023-01-11

荟萃分析显示,标签外低剂量不减少出血结局,但增加全因死亡风险(HR=1.28,95%CI 1.10-1.49,p=0.006);高剂量增加大出血风险(HR=1.41,95%CI 1.07-1.85,p=0.013)。高龄、轻微出血史、高血压、充血性心衰和低肌酐清除率与低剂量相关。

要点

  • 标签外低剂量NOAC不减少出血,但增加全因死亡风险。
  • 标签外高剂量NOAC增加大出血风险。
  • 高龄、轻微出血史、高血压、心衰和低CrCl与低剂量相关。

核心结论

  • 标签外低剂量NOAC不减少出血结局,但增加全因死亡风险。
  • 标签外高剂量NOAC增加大出血风险。
  • 处方者应遵循NOAC剂量指南以优化房颤患者临床结局。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane Library、International Pharmaceutical Abstracts、Econlit、PubMed和NHS EEDs数据库。
  • 纳入2008至2020年发表的英文观察性研究,评估成人房颤患者不适当NOAC剂量的结局或相关因素。

主要发现

  • 荟萃分析显示,与推荐NOAC剂量相比,标签外低剂量对卒中结局(缺血性卒中、卒中/TIA、卒中/SE、卒中/SE/TIA)无显著影响。
  • 15项研究荟萃分析显示,低剂量对大出血无显著影响(HR=1.04,95%CI 0.90-1.19,p=0.625),但增加全因死亡风险(HR=1.28,95%CI 1.10-1.49,p=0.006)。
  • 高剂量增加大出血风险(HR=1.41,95%CI 1.07-1.85,p=0.013)。
  • 未发现评估不适当NOAC剂量经济结局的研究。
  • 12项研究叙述性合成显示,高龄、轻微出血史、高血压、充血性心衰和低肌酐清除率(CrCl)与低剂量风险增加相关;高剂量驱动因素证据不足。

关键数值与推荐

  • 低剂量与大出血:HR=1.04,95%CI 0.90-1.19,p=0.625。
  • 低剂量与全因死亡:HR=1.28,95%CI 1.10-1.49,p=0.006。
  • 高剂量与大出血:HR=1.41,95%CI 1.07-1.85,p=0.013。

临床怎么用

  • 处方NOAC时应严格遵循剂量指南,避免标签外低剂量或高剂量。
  • 对高龄、有轻微出血史、高血压、心衰或低CrCl的患者,应警惕低剂量风险但仍需按指南调整。

局限性

  • 仅纳入英文观察性研究,可能存在选择偏倚。
  • 未发现经济结局研究,无法评估成本影响。
  • 高剂量驱动因素证据不足,无法充分评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There has been limited systematic evaluation of outcomes and drivers of inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients with atrial fibrillation (AF). This review identified and systematically evaluated literature on clinical and economic outcomes of inappropriate NOAC dosing and associated patient characteristics. METHODS: MEDLINE, Embase, Cochrane Library, International Pharmaceutical Abstracts, Econlit, PubMed and NHS EEDs databases were searched for English language observational studies from all geographies published between 2008 and 2020, examining outcomes of, or factors associated with, inappropriate NOAC dosing in adult patients with AF. RESULTS: One hundred and six studies were included in the analysis. Meta-analysis showed that compared with recommended NOAC dosing, off-label underdosing was associated with a null effect on stroke outcomes (ischaemic stroke and stroke/transient ischaemic attack (TIA), stroke/systemic embolism (SE) and stroke/SE/TIA). Meta-analysis of 15 studies examining clinical outcomes of inappropriate NOAC dosing found a null effect of underdosing on bleeding outcomes (major bleeding HR=1.04, 95% CI 0.90 to 1.19; p=0.625) but an increased risk of all-cause mortality (HR=1.28, 95% CI 1.10 to 1.49; p=0.006). Overdosing was associated with an increased risk of major bleeding (HR=1.41, 95% CI 1.07 to 1.85; p=0.013). No studies were found examining economic outcomes of inappropriate NOAC dosing. Narrative synthesis of 12 studies examining drivers of inappropriate NOAC dosing found that increased age, history of minor bleeds, hypertension, congestive heart failure and low creatine clearance (CrCl) were associated with an increased risk of underdosing. There was insufficient evidence to assess drivers of overdosing. CONCLUSIONS: Our analysis suggests that off-label underdosing of NOACs does not reduce bleeding outcomes. Patients prescribed off-label NOAC doses are at an increased risk of all-cause mortality. These data underscore the importance of prescriber adherence to NOAC dosing guidelines to achieve optimal clinical outcomes for patients with AF. PROSPERO REGISTRATION NUMBER: CRD42020219844.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Caso, de Groot, Sanmartin Fernandez, et al. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Heart. 2023. PMID: 36316100. doi:10.1136/heartjnl-2022-321114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。